<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Dongkook Pharmaceutical on Korea Invest Insights</title><link>https://koreainvestinsights.com/tags/dongkook-pharmaceutical/</link><description>Recent content in Dongkook Pharmaceutical on Korea Invest Insights</description><generator>Hugo -- gohugo.io</generator><language>en</language><copyright>koreainvestinsights.com · @korea_invest_insights</copyright><lastBuildDate>Fri, 13 Nov 2026 23:34:41 +0900</lastBuildDate><atom:link href="https://koreainvestinsights.com/tags/dongkook-pharmaceutical/feed.xml" rel="self" type="application/rss+xml"/><item><title>Korea Quality Re-Rating Watch 2026-11-13: Dongkook, Coses, Celltrion</title><link>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-13/</link><pubDate>Fri, 13 Nov 2026 16:30:00 +0900</pubDate><guid>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-13/</guid><description>&lt;h2 id="macro-dashboard"&gt;Macro Dashboard
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Indicator&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Level&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Change&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSPI&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5,290.5&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+5.4% (5-day window)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSDAQ&lt;/td&gt;
 &lt;td style="text-align: right"&gt;699.7&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+9.5% (5-day window)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;USD/KRW&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,336&lt;/td&gt;
 &lt;td style="text-align: right"&gt;-2.0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;VIX&lt;/td&gt;
 &lt;td style="text-align: right"&gt;18.4&lt;/td&gt;
 &lt;td style="text-align: right"&gt;-7.8%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Brent&lt;/td&gt;
 &lt;td style="text-align: right"&gt;$95.7&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+3.4%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;US 10Y&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5.10%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+0.24pp&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Regime verdict:&lt;/strong&gt; Korea is withheld. The raw signal reads Bear, but one input is stale (futures open interest, 3 sessions old), so the label was not committed. US is Neutral. The 10-year yield rise breached the model&amp;rsquo;s 0.15pp threshold.&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Data note:&lt;/strong&gt; Index levels are Yahoo quotes that may be intraday. The daily-bar close was 5,315.45 for KOSPI and 708.22 for KOSDAQ. Changes are 5-day windows, not one-day moves.&lt;/li&gt;
&lt;/ul&gt;
&lt;h2 id="market-wrap"&gt;Market Wrap
&lt;/h2&gt;&lt;p&gt;The Korea stock market bounced hard this week, but participation is still narrow. KOSPI is up 5.4% and KOSDAQ 9.5% over five days. Only 21.0% of the 2,692 stocks screened trade above their 50-day average. For the 200-day average the share is 15.6%. Both KOSPI and KOSDAQ remain below their 200-day averages.&lt;/p&gt;
&lt;p&gt;Today was selective. Of 2,592 stocks, 1,196 rose, 1,130 fell and 266 were flat. The advance/decline ratio was 105.8, and the average stock gained 0.20%.&lt;/p&gt;
&lt;p&gt;Financials led. KB Financial (105560.KS) gained 4.74%. Hana Financial (086790.KS) rose 3.40%. BNK Financial (138930.KS) climbed 6.48%. Brokers also moved up. Samsung Securities (016360.KS) added 3.50% and NH Investment &amp;amp; Securities (005940.KS) 3.39%.&lt;/p&gt;
&lt;p&gt;Utilities and internet names lagged. KEPCO (015760.KS) dropped 9.79%. NAVER (035420.KS) fell 5.12%. Doosan (000150.KS) lost 8.55%.&lt;/p&gt;
&lt;p&gt;Flow data pointed in two directions. Foreign investors were top net buyers of Samsung SDI (006400.KS), KB Financial, Hyundai Motor (005380.KS) and Hana Financial. They were top net sellers of KEPCO, NAVER and Samsung Securities. Institutions bought brokers and financials, including Samsung Securities, Korea Investment Holdings (071050.KS) and NH Investment &amp;amp; Securities. They sold NAVER, KEPCO and Doosan. The source gives rankings only, with no amounts.&lt;/p&gt;
&lt;p&gt;The derivatives picture is mixed. Program trading showed net buying of about 339 billion won on Nov 12. Futures basis was -6.07, which means futures traded below spot. ETF net creation was about 1.55 trillion won on Nov 11. These figures are one to two sessions old.&lt;/p&gt;
&lt;h2 id="todays-quality-re-rating-candidates"&gt;Today&amp;rsquo;s Quality Re-Rating Candidates
&lt;/h2&gt;&lt;p&gt;The framework has three layers. &lt;strong&gt;Quality&lt;/strong&gt; asks whether the business earns good returns. &lt;strong&gt;Money flow&lt;/strong&gt; asks whether foreign and institutional buyers are absorbing retail selling. &lt;strong&gt;Re-rating&lt;/strong&gt; asks whether earnings or the cycle are improving enough for the market to reprice the stock.&lt;/p&gt;
&lt;p&gt;The KR Meta Screener ranks names by family score. Historically, the financial-factor families (Quality, Smart Money Quality, Cycle, Smart Money Earnings) added little in forward-return tests. Estimate-upgrade signals added the most. The meta order is therefore not the same as a simple overlap count. The Intersection Summary found no 2+ overlap among the PEAD source it included today, so the meta list is the primary queue.&lt;/p&gt;
&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th style="text-align: right"&gt;Meta rank&lt;/th&gt;
 &lt;th&gt;Ticker&lt;/th&gt;
 &lt;th&gt;Name&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Families&lt;/th&gt;
 &lt;th&gt;Key metrics&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td&gt;086450.KQ&lt;/td&gt;
 &lt;td&gt;Dongkook Pharmaceutical&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;ROE 9.9%, OP +20.1% YoY, 5-day foreign + quality-institution net buying 4.6bn won&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;089890.KQ&lt;/td&gt;
 &lt;td&gt;Coses&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;Q3 OP +3,432% YoY, OPM 30.0%, 5-day return +41.6%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;002900.KS&lt;/td&gt;
 &lt;td&gt;TYM&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;Estimate revision z +0.76, buyback decided Nov 11&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;068270.KS&lt;/td&gt;
 &lt;td&gt;Celltrion&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Foreign + institution 5-day net buying 54.1bn won, retail selling 97.2bn won&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;064290.KQ&lt;/td&gt;
 &lt;td&gt;Intekplus&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;Estimate revision z +0.62, supply contract Nov 9, flow caution&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;6&lt;/td&gt;
 &lt;td&gt;002790.KS&lt;/td&gt;
 &lt;td&gt;Amorepacific Holdings&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;RS80 leadership, quiet foreign accumulation, treasury share disposal&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;7&lt;/td&gt;
 &lt;td&gt;026960.KS&lt;/td&gt;
 &lt;td&gt;Dongsuh&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;RS80 not-late, foreign holdings rising&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;8&lt;/td&gt;
 &lt;td&gt;089590.KS&lt;/td&gt;
 &lt;td&gt;Jeju Air&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td&gt;Estimate revision z +5.10, retail selling absorbed&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;strong&gt;Dongkook Pharmaceutical (086450.KQ)&lt;/strong&gt; is the only name hitting four families: Quality Compounder, Smart Money Quality, Cycle Rerating and PEAD. Foreign and quality-institution investors absorbed 5.3bn won of retail selling. The only recent filing is a routine shareholder-meeting notice. The financials behind the screen are FY2025 Q4 data, 246 days old. Next check: whether Q3 results confirm the margin gain, which is only +0.5pp.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Coses (089890.KQ)&lt;/strong&gt;, a semiconductor equipment maker, has the strongest earnings headline. Q3 revenue rose 76.9%, with margin up 29.2pp from a low base. The Nov 12 quarterly report is on file, and two supply-contract amendments are logged as catalysts. The stock is up 41.6% in five days, so chase risk is high. Next check: the contract sizes and whether the flow persists after the jump.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;TYM (002900.KS)&lt;/strong&gt;, a tractor maker, appears on upward estimate revisions and PEAD. A buyback decision (Nov 11) and a Q3 report (Nov 13) are the catalysts. The PEAD metrics come from a Q2 snapshot, so the Q3 filing needs a re-check.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Celltrion (068270.KS)&lt;/strong&gt; sits at meta rank 4 despite the highest family score (69.2). Its three families are Smart Money Quality, Cycle Rerating and RS80 leadership. It filed a treasury-share buyback result on Nov 13. The margin figure (+14.2pp) also uses FY2025 Q4 data and needs a refresh.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Caution:&lt;/strong&gt; Intekplus (064290.KQ) shows foreign and quality-institution net selling of 7.4bn won over five days, absorbed by retail buyers. That runs against the flow layer.&lt;/p&gt;
&lt;p&gt;These are screened candidates for follow-up research, not recommendations.&lt;/p&gt;</description></item><item><title>Korea Quality Re-Rating Watch 11-12: Dongkook, TYM, Celltrion</title><link>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-12/</link><pubDate>Thu, 12 Nov 2026 16:30:00 +0900</pubDate><guid>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-12/</guid><description>&lt;h2 id="macro-dashboard"&gt;Macro Dashboard
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Indicator&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Level&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Change&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSPI&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5,342.73&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+5.59% (5-day window)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSDAQ&lt;/td&gt;
 &lt;td style="text-align: right"&gt;696.53&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+8.11% (5-day window)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;USD/KRW&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,331.9&lt;/td&gt;
 &lt;td style="text-align: right"&gt;-1.80%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;VIX&lt;/td&gt;
 &lt;td style="text-align: right"&gt;18.32&lt;/td&gt;
 &lt;td style="text-align: right"&gt;-28.55%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Brent&lt;/td&gt;
 &lt;td style="text-align: right"&gt;$92.05&lt;/td&gt;
 &lt;td style="text-align: right"&gt;-0.56%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;US 10Y&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5.00%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+0.16pp&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;strong&gt;Regime verdict:&lt;/strong&gt; Korea is withheld (UNKNOWN). The raw model signal is Bear, but one derivatives input (open interest) is two sessions old, so the label was not committed. The US is Neutral. It was downgraded from Bull because the 10-year yield rose more than 0.15pp.&lt;/p&gt;
&lt;p&gt;The index changes above are five-day windows built from Yahoo data. The source does not give a one-day change. The FinanceDataReader daily close was lower: 5,305.47 for KOSPI and 688.45 for KOSDAQ. Both indices sit well below their 200-day averages (KOSPI 6,520, KOSDAQ 961).&lt;/p&gt;
&lt;h2 id="market-wrap"&gt;Market Wrap
&lt;/h2&gt;&lt;p&gt;The KOSPI and Korea stock market bounce is real at the index level. The average stock told a different story today.&lt;/p&gt;
&lt;p&gt;Of 2,595 stocks, 743 rose, 1,591 fell and 261 were flat. The advance/decline proxy was 46.7 and the average stock fell 0.76%. Only 20.1% of the 2,692 stocks in the screening universe trade above their 50-day average. That figure is 15.2% against the 200-day average. This was a selective, narrow session, not a broad rally.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Weak spots:&lt;/strong&gt; Several mid-caps fell sharply and appeared on the foreign selling list. DB HiTek (000990.KS) fell 16.36%, Dalba Global (483650.KS) fell 13.97%, and SPG (058610.KS) fell 16.09%. On the institutional selling list, NC (036570.KS) fell 9.19%, NAVER (035420.KS) fell 6.43% and Meritz Financial Holdings (138040.KS) fell 13.05%. Hyundai Motor (005380.KS) fell 2.20%.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Flow signals:&lt;/strong&gt; Foreigners ranked financials high among net buyers: KB Financial (105560.KS), Shinhan Financial (055550.KS) and Hana Financial (086790.KS), even though KB and Shinhan slipped. Institutions were net sellers of the same three names. Institutions bought smaller, higher-volatility names such as Estec (069510.KS, +19.83%), HYBE (352820.KS, +5.35%) and Samyang Foods (003230.KS, +4.46%). The source gives rankings only. Net buying amounts and turnover were not available.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Derivatives and passive flow:&lt;/strong&gt; Program trading was a net buy of about 338.9 billion won. Basis was -6.07, and net ETF creation was about 1.55 trillion won. Open interest was 83,678, but that reading dates from Nov 10.&lt;/p&gt;
&lt;p&gt;The macro backdrop is mixed. The won strengthened and VIX fell. The US 10-year yield rose to 5.00%, and the dollar index rose to 102.9.&lt;/p&gt;
&lt;h2 id="todays-quality-re-rating-candidates"&gt;Today&amp;rsquo;s Quality Re-Rating Candidates
&lt;/h2&gt;&lt;p&gt;The screen asks for three layers. The first is &lt;strong&gt;quality&lt;/strong&gt;: a business with solid returns and growing profit. The second is &lt;strong&gt;money flow&lt;/strong&gt;: foreign and quality-institution buying that absorbs individual selling. The third is a &lt;strong&gt;re-rating or earnings catalyst&lt;/strong&gt;: margin expansion, estimate upgrades, or post-earnings drift (PEAD).&lt;/p&gt;
&lt;p&gt;The strict overlap check found no stock in two or more of the screeners it reads. That check read only the PEAD screener today. The KR Meta Screener, which combines several screener families, supplies the ranking below. Its weights favor consensus-upgrade signals (weight 2.18) over the four financial-factor screens (0.54), which have lagged their candidate pool recently.&lt;/p&gt;
&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th style="text-align: right"&gt;Rank&lt;/th&gt;
 &lt;th&gt;Ticker&lt;/th&gt;
 &lt;th&gt;Name&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Families&lt;/th&gt;
 &lt;th&gt;Key metrics&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td&gt;086450.KS&lt;/td&gt;
 &lt;td&gt;Dongkook Pharmaceutical&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;ROE 9.9%, OP +20.1% YoY, margin +0.5pp, RS 90&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;002900.KS&lt;/td&gt;
 &lt;td&gt;TYM&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;Consensus z +0.74, OP +298% YoY, buyback decision Nov 11&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;068270.KS&lt;/td&gt;
 &lt;td&gt;Celltrion&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;OP +137.5% YoY, margin +14.2pp, 4 catalyst filings&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;121600.KQ&lt;/td&gt;
 &lt;td&gt;Nano Advanced Materials&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;5-day foreign + quality-institution buying +17.2bn won, margin +0.8pp&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;002790.KS&lt;/td&gt;
 &lt;td&gt;Amorepacific Holdings&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;Quiet accumulation, pivot gap +5.0%, RS80 pass&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;6&lt;/td&gt;
 &lt;td&gt;089590.KS&lt;/td&gt;
 &lt;td&gt;Jeju Air&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td&gt;Consensus z +5.10, individual selling absorbed (14.2bn won)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;7&lt;/td&gt;
 &lt;td&gt;272450.KS&lt;/td&gt;
 &lt;td&gt;Jin Air&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td&gt;Consensus z +0.67, two IR filings&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;8&lt;/td&gt;
 &lt;td&gt;020150.KS&lt;/td&gt;
 &lt;td&gt;Lotte Energy Materials&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td&gt;Consensus z +1.42, 5 catalyst filings&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;strong&gt;Dongkook Pharmaceutical (086450.KS)&lt;/strong&gt; is a Korean drugmaker. It leads because four screener families flag it: Quality Compounder, Cycle Rerating, PEAD and Quiet Accumulation. Foreign and quality-institution buyers absorbed about 4.9 billion won of individual selling. The only recent DART filing is a shareholder meeting notice, so no company-specific catalyst is visible. The financials come from the 2025 annual filing, which is 245 days old. The next check is the latest quarterly report, to confirm the margin trend still holds.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;TYM (002900.KS)&lt;/strong&gt; makes agricultural machinery. Its case rests on estimate upgrades and official events. The company filed a treasury share buyback decision on Nov 11 and preliminary earnings on Nov 4. The PEAD screen shows operating profit up about 298% year on year, but that figure comes from a snapshot source with no filing date. It is a growth filter, not a consensus surprise. Check the earnings release and the buyback size.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Celltrion (068270.KS)&lt;/strong&gt; is a biosimilar maker. It is flagged for margin expansion (+14.2pp), PEAD and RS80 leadership, and about 100 billion won of individual selling was absorbed by foreign and quality-institution buyers. DART shows a catalyst filing on Nov 2: a European Phase 3 trial plan for its CTP13 subcutaneous product in rheumatoid arthritis. The financial data is also from the 2025 annual filing. The next check is the Q3 numbers and the trial timeline.&lt;/p&gt;
&lt;p&gt;Nano Advanced Materials (121600.KQ) has the strongest money-flow evidence outside the top three. It also filed a share cancellation decision today. Korean Air (003490.KS) and Samah Aluminum (006110.KS) appear in the full ranking, with consensus upgrades as their only screen signal.&lt;/p&gt;
&lt;p&gt;All names are screened candidates for further research, not recommendations. KT Genie Music (043610.KS) carries one DART risk-type filing and is excluded from the top table.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Sources: KR Meta Screener, KR PEAD screener, macro regime model and Research OS snapshot, all dated 2026-11-12. Yahoo index levels are intraday-capable regular market prices.&lt;/em&gt;&lt;/p&gt;</description></item><item><title>Korea Quality Re-Rating Watch 2026-11-05: Dongkook, Hanmi &amp; HMM</title><link>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-05/</link><pubDate>Thu, 05 Nov 2026 16:30:00 +0900</pubDate><guid>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-05/</guid><description>&lt;h2 id="macro-dashboard--2026-11-05"&gt;Macro Dashboard — 2026-11-05
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Indicator&lt;/th&gt;
 &lt;th&gt;Level&lt;/th&gt;
 &lt;th&gt;5-Day Δ&lt;/th&gt;
 &lt;th&gt;Signal&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSPI&lt;/td&gt;
 &lt;td&gt;5,383.8&lt;/td&gt;
 &lt;td&gt;−6.1%&lt;/td&gt;
 &lt;td&gt;Bear&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSDAQ&lt;/td&gt;
 &lt;td&gt;678.4&lt;/td&gt;
 &lt;td&gt;−6.4%&lt;/td&gt;
 &lt;td&gt;Bear&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;VIX&lt;/td&gt;
 &lt;td&gt;16.82&lt;/td&gt;
 &lt;td&gt;−2.2%&lt;/td&gt;
 &lt;td&gt;Stable&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;US 10Y&lt;/td&gt;
 &lt;td&gt;4.89%&lt;/td&gt;
 &lt;td&gt;−0.09pp&lt;/td&gt;
 &lt;td&gt;Flat&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;USD/KRW&lt;/td&gt;
 &lt;td&gt;1,342.8&lt;/td&gt;
 &lt;td&gt;+0.4%&lt;/td&gt;
 &lt;td&gt;Flat&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Brent&lt;/td&gt;
 &lt;td&gt;$96.2&lt;/td&gt;
 &lt;td&gt;−8.2%&lt;/td&gt;
 &lt;td&gt;Falling&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;DXY&lt;/td&gt;
 &lt;td&gt;101.5&lt;/td&gt;
 &lt;td&gt;−0.7%&lt;/td&gt;
 &lt;td&gt;Flat&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;strong&gt;Regime: KR Bear | US Bull&lt;/strong&gt; (11/12 inputs verified). Only 16.7% of Korean stocks trade above their 50-day moving average; 40.3% of US stocks do. VIX at 16.8 and US yields drifting lower confirm this is a Korea-specific drawdown, not a global risk-off event.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="market-wrap"&gt;Market Wrap
&lt;/h2&gt;&lt;p&gt;Korea&amp;rsquo;s November 5 session was a broad, technically-driven sell-off with two distinct pockets of institutional support cutting against the tide.&lt;/p&gt;
&lt;p&gt;The aggregate picture leaves little room for interpretation: 1,714 stocks fell, 635 rose, and the average stock declined 1.96%. Program selling totaled ₩1.69 trillion net while ETF redemptions reached ₩1.52 trillion. Futures basis sat at −0.53. This is systematic passive de-risking — not a single-sector event.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Where money entered.&lt;/strong&gt; Internet and platform names were the session&amp;rsquo;s standout. NAVER (035420.KS, +8.26%) attracted simultaneous foreign and institutional net buying — a rare alignment on a down day. Kakao (035720.KS, +10.65%) drew the heaviest foreign inflows of any name. Hybe (352820.KS, +8.19%) also saw foreign accumulation. The likely driver: falling oil prices and stabilizing US yields created a rotation window into domestic internet names that had lagged through October.&lt;/p&gt;
&lt;p&gt;Financials were the second destination for institutional flows. KB Financial (105560.KS, +3.63%), Woori Financial (316140.KS, +5.27%), Hyundai Mobis (012330.KS, +2.54%), Hyundai Motor (005380.KS, +3.53%), and Hana Financial (086790.KS, +3.16%) all recorded institutional net buying. Samsung Biologics (207940.KS, +1.67%) was bought by institutions even as foreign investors trimmed. Koryo Zinc (010130.KS, +11.0%) surged with institutional support; foreign investors were on the other side.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Where money exited.&lt;/strong&gt; Semiconductors and the battery supply chain bore the heaviest institutional selling. PSK Holdings (031980.KS, −19.4%), Lotte Energy Materials (020150.KS, −18.4%), Doosan (000150.KS, −17.5%), TES (095610.KS, −17.1%), and Doosan Tesna (131970.KS, −16.1%) all saw combined foreign and institutional selling. Samsung SDI (006400.KS, −6.6%) and S-Oil (010950.KS, −6.2%) declined as institutions distributed. The common thread across the losers: capex-intensive businesses where slowing order visibility or margin pressure makes the near-term earnings trajectory harder to defend.&lt;/p&gt;
&lt;p&gt;The split is clean. Quality internet and financial franchises absorbed institutional flows; semis, batteries, and energy supply chain were the exits. With KOSPI and KOSDAQ both trading more than 20% below their 200-day moving averages, the structural backdrop remains broken. But within that environment, some businesses are being selectively re-priced higher.&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Note: Same-day full close briefing unavailable; this section is sourced from the same-day Research OS market snapshot.&lt;/em&gt;&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="todays-quality-re-rating-candidates"&gt;Today&amp;rsquo;s Quality Re-Rating Candidates
&lt;/h2&gt;&lt;p&gt;The KR Meta Screener evaluated 109 tickers and ranked 20 article candidates for November 5. The PEAD screener produced no 2+ overlap candidates on its own today. The meta screener&amp;rsquo;s multi-family scoring identifies the stronger setups, where quality fundamentals, money flow, and an earnings or cycle catalyst converge.&lt;/p&gt;
&lt;h3 id="top-candidates-meta-screener-rank"&gt;Top Candidates (Meta Screener Rank)
&lt;/h3&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th style="text-align: right"&gt;Rank&lt;/th&gt;
 &lt;th&gt;Ticker&lt;/th&gt;
 &lt;th&gt;Name&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Meta Score&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Families&lt;/th&gt;
 &lt;th&gt;Screeners Hit&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td&gt;086450.KS&lt;/td&gt;
 &lt;td&gt;Dongkook Pharmaceutical&lt;/td&gt;
 &lt;td style="text-align: right"&gt;76.7&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;Quality, Cycle Rerating, PEAD, Quiet Accumulation, RS80&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;128940.KS&lt;/td&gt;
 &lt;td&gt;Hanmi Pharma&lt;/td&gt;
 &lt;td style="text-align: right"&gt;53.8&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2 (5 evidence)&lt;/td&gt;
 &lt;td&gt;Smart Money Quality, Cycle Rerating, Consensus Up, Smart Money Earnings&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;011200.KS&lt;/td&gt;
 &lt;td&gt;HMM&lt;/td&gt;
 &lt;td style="text-align: right"&gt;36.8&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Consensus Up, Quiet Accumulation, RS80&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;089860.KS&lt;/td&gt;
 &lt;td&gt;Lotte Rental&lt;/td&gt;
 &lt;td style="text-align: right"&gt;35.6&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Cycle Rerating, Quiet Accumulation, RS80 + same-day DART prelim&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;036460.KS&lt;/td&gt;
 &lt;td&gt;KOGAS&lt;/td&gt;
 &lt;td style="text-align: right"&gt;30.6&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2 (5 evidence)&lt;/td&gt;
 &lt;td&gt;Quiet Accumulation, RS80, Kiwoom surface + buyback DART&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;6&lt;/td&gt;
 &lt;td&gt;030000.KS&lt;/td&gt;
 &lt;td&gt;Cheil Worldwide&lt;/td&gt;
 &lt;td style="text-align: right"&gt;29.6&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2 (4 evidence)&lt;/td&gt;
 &lt;td&gt;Quiet Accumulation, RS80 + same-day DART prelim&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;7&lt;/td&gt;
 &lt;td&gt;071970.KS&lt;/td&gt;
 &lt;td&gt;HD Hyundai Marine Engine&lt;/td&gt;
 &lt;td style="text-align: right"&gt;19.7&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2 (4 evidence)&lt;/td&gt;
 &lt;td&gt;Consensus Up, Kiwoom surface + 3 DART catalysts&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;8&lt;/td&gt;
 &lt;td&gt;089590.KS&lt;/td&gt;
 &lt;td&gt;Jeju Air&lt;/td&gt;
 &lt;td style="text-align: right"&gt;22.8&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1 (3 evidence)&lt;/td&gt;
 &lt;td&gt;Consensus Up (z +5.88), IR event DART&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;h3 id="top-3-in-detail"&gt;Top 3 in Detail
&lt;/h3&gt;&lt;p&gt;&lt;strong&gt;#1 — Dongkook Pharmaceutical (086450.KS, Score 76.7)&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Dongkook is a mid-cap Korean pharma spanning OTC topical drugs, prescription products, and health supplements. It leads today&amp;rsquo;s candidates because it registers across the most independent screener families: Quality Compounder (ROE 9.9%, operating profit YoY +20.1%), Cycle Rerating (margin expansion +0.5pp), Quiet Accumulation (foreign ownership rising in a compressed price range, retail selling ₩7.6bn absorbed by institutional and foreign buyers), RS80 not-late leadership (MA50 premium +10.5%, 20-day flow momentum +22%), and Tier C of the PEAD screener (OP growth +20%, margin +0.52pp). The convergence of quality fundamentals and quiet buying pressure in a down market is the signal. Key caveat: the PEAD financial data is based on FY2025Q4 (filing age 238 days). The next verification is a fresh 1H2026 earnings release that either confirms or cancels the margin expansion story.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;#2 — Hanmi Pharma (128940.KS, Score 53.8)&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Hanmi is one of Korea&amp;rsquo;s most active drug-licensing platforms, with a deepening pipeline in obesity and rare diseases. Today it hits Smart Money Quality (net foreign + institutional buying of ₩60.3bn over five days), Cycle Rerating (margin expansion +2.2pp — the strongest margin signal among all candidates today), Consensus Up Revision, and Smart Money Earnings. Retail sold ₩55bn; institutional and foreign absorbed. A live DART catalyst reinforces the picture: an October 30 technology-transfer agreement for the Fabry disease treatment LAGLA. The core question for follow-up research is whether the consensus revision is driven by this single licensing event — making it one-time — or by underlying pipeline momentum that sustains the margin improvement into 2H2026.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;#3 — HMM (011200.KS, Score 36.8)&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;HMM is Korea&amp;rsquo;s largest container shipping company. It qualifies via Consensus Up Revision (composite z-score +0.53), Quiet Accumulation (foreign ownership rising in a narrow price range, retail selling ₩34.6bn absorbed by institutional and foreign flows), and RS80 Not-Late Leadership (pivot gap +6.9%, Focus Candidate classification, 20-day supply-demand momentum +22.5%). A DART disclosure filed October 15 shows new facility investment, potentially signaling fleet expansion plans. With Brent crude falling 8.2% over five days, shipping input costs are easing — a potential margin tailwind that may explain the consensus upgrade. The critical next check is whether spot shipping rates (BDI, CCFI) are recovering to validate the earnings revision, or whether the upgrade is running ahead of fundamentals.&lt;/p&gt;
&lt;hr&gt;
&lt;p&gt;&lt;em&gt;Source: Research OS macro-regime data (11/12 inputs current), same-day KR market snapshot, and KR Meta Screener as of 2026-11-05. This post is market analysis and does not constitute investment advice.&lt;/em&gt;&lt;/p&gt;</description></item></channel></rss>